Petru Cristian Simon1, Antonio Vallano. Show Affiliations » 1. Servicio de Farmacología Clínica, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, España.
Abstract
Entities: Disease
Mesh： See more » Abnormalities, Drug-Induced/epidemiologyAbnormalities, Drug-Induced/etiologyAbortion, Spontaneous/chemically inducedAbortion, Spontaneous/epidemiologyAdalimumabAntibodies, Monoclonal/adverse effectsAntibodies, Monoclonal/pharmacologyAntibodies, Monoclonal/therapeutic useAntibodies, Monoclonal, Humanized/adverse effectsAntibodies, Monoclonal, Humanized/pharmacologyAntibodies, Monoclonal, Humanized/therapeutic useBiological Products/adverse effectsBiological Products/pharmacologyBiological Products/therapeutic useCertolizumab PegolClinical Trials as TopicCohort StudiesDrug LabelingEtanerceptFemaleFetus/drug effectsFetus/immunologyHumansImmunoglobulin Fab Fragments/adverse effectsImmunoglobulin Fab Fragments/pharmacologyImmunoglobulin Fab Fragments/therapeutic useImmunoglobulin G/adverse effectsImmunoglobulin G/pharmacologyImmunoglobulin G/therapeutic useInfant, NewbornInfliximabMaternal-Fetal ExchangePolyethylene Glycols/adverse effectsPolyethylene Glycols/pharmacologyPolyethylene Glycols/therapeutic usePregnancyPregnancy Complications/chemically inducedPregnancy Complications/drug therapyPregnancy OutcomePregnancy Trimester, ThirdPuerperal Disorders/chemically inducedPuerperal Disorders/epidemiologyReceptors, Tumor Necrosis Factor/therapeutic useRegistriesTumor Necrosis Factor-alpha/antagonists & inhibitorsVaccination
Substances： See more » Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedBiological ProductsImmunoglobulin Fab FragmentsImmunoglobulin GReceptors, Tumor Necrosis FactorTumor Necrosis Factor-alphaPolyethylene GlycolsInfliximabAdalimumabEtanerceptCertolizumab Pegol
Year: 2013 PMID： 23702347 DOI： 10.1016/j.medcli.2013.04.005
Source DB: PubMed Journal: Med Clin (Barc) ISSN： 0025-7753 Impact factor: 1.725